Edesa Biotech, Inc. (EDSA)

NCM – Цена в реальном времени. Валюта: USD

13.27

-2.01 (-13.15%)

При закрытии: May 12, 2026, 4:00 PM EDT

14.01

+0.74 (5.58%)

До открытия: May 13, 2026, 4:27 AM EDT

31.03.2026

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients

26.03.2026

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on preparations and reaffirmed enrollment timeline guidance for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo. The announcement coincides with the company's sponsorship and participation today at the Global Vitiligo Foundation (GVF) Annual Scientific Symposium in Denver, Colorado.

24.02.2026

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today positive additional data from a Phase 3 study of paridiprubart.

13.02.2026

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business.

12.12.2025

Edesa Biotech Reports Fiscal Year 2025 Results

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business.

31.10.2025

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences:

28.10.2025

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announced positive results from a Phase 3 study evaluating the company's drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure.

Видео

No Data

There is no data to display

Пресс-релизы

31.03.2026

Edesa Biotech, Inc. (EDSA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Edesa Biotech, Inc. (EDSA)

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Видео

No Data

Пресс-релизы

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Видео

No Data

Пресс-релизы

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Search stocks

Edesa Biotech, Inc. (EDSA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Edesa Biotech, Inc. (EDSA)

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Видео

No Data

Пресс-релизы

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Видео

No Data

Пресс-релизы

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results